Publication Date
11-1-2023
Journal
Molecular Psychiatry
DOI
10.1038/s41380-023-02260-3
PMID
37730845
PMCID
PMC10914626
PubMedCentral® Posted Date
9-20-2023
PubMedCentral® Full Text Version
Post-Print
Published Open-Access
yes
Keywords
Animals, Humans, Mice, Bipolar Disorder, Calcium-Calmodulin-Dependent Protein Kinase Kinase, Mutation, Missense, Bipolar disorder, Biochemistry
Abstract
Current pharmacological treatments for bipolar disorder are inadequate and based on serendipitously discovered drugs often with limited efficacy, burdensome side-effects, and unclear mechanisms of action. Advances in drug development for the treatment of bipolar disorder remain incremental and have come largely from repurposing drugs used for other psychiatric conditions, a strategy that has failed to find truly revolutionary therapies, as it does not target the mood instability that characterises the condition. The lack of therapeutic innovation in the bipolar disorder field is largely due to a poor understanding of the underlying disease mechanisms and the consequent absence of validated drug targets. A compelling new treatment target is the Ca
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Life Sciences Commons, Medical Cell Biology Commons, Medical Microbiology Commons, Medical Molecular Biology Commons, Medical Specialties Commons, Mental and Social Health Commons